[Ocular mucous membrane pemphigoid].
Okuläres Schleimhautpemphigoid.
Autoimmune disease
Immunosuppression
Inflammation
Scarring conjunctivitis
Symblepharon
Journal
Die Ophthalmologie
ISSN: 2731-7218
Titre abrégé: Ophthalmologie
Pays: Germany
ID NLM: 9918402288106676
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
accepted:
15
05
2023
medline:
10
7
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Mucous membrane pemphigoid refers to a heterogeneous group of autoimmune diseases with subepidermal blister formation that can affect all mucous membranes with varying frequencies. This is a rare disease without any geographic or sexual predisposition that is characterized by recurrent inflammation and progressive scarring. The specific diagnostics can be negative in up to 50% of cases. The diagnosis is predominantly made in patients aged 60-80 years. Ophthalmologists play an important role in the care of affected individuals as the conjunctiva is the second most frequent site of involvement. The treatment is often tedious and primarily consists of long-term systemic immunosuppression. Das Schleimhautpemphigoid umfasst eine heterogene Gruppe von Autoimmunerkrankungen mit subepidermaler Blasenbildung, die alle Schleimhäute mit unterschiedlichen Häufigkeiten betreffen kann. Es handelt sich um eine seltene Erkrankung ohne geografische oder sexuelle Prädisposition, die durch rezidivierende Entzündungen und fortschreitende Vernarbung gekennzeichnet ist. Die spezifische Diagnostik kann in bis zu 50 % der Fälle negativ ausfallen. Die Diagnose wird überwiegend bei 60- bis 80-jährigen Patienten gestellt. Da die Konjunktiva die zweithäufigste Beteiligung darstellt, spielen Augenärzte eine wichtige Rolle bei der Versorgung der Betroffenen. Die Therapie ist oft langwierig und besteht primär in einer systemischen Immunsuppression.
Autres résumés
Type: Publisher
(ger)
Das Schleimhautpemphigoid umfasst eine heterogene Gruppe von Autoimmunerkrankungen mit subepidermaler Blasenbildung, die alle Schleimhäute mit unterschiedlichen Häufigkeiten betreffen kann. Es handelt sich um eine seltene Erkrankung ohne geografische oder sexuelle Prädisposition, die durch rezidivierende Entzündungen und fortschreitende Vernarbung gekennzeichnet ist. Die spezifische Diagnostik kann in bis zu 50 % der Fälle negativ ausfallen. Die Diagnose wird überwiegend bei 60- bis 80-jährigen Patienten gestellt. Da die Konjunktiva die zweithäufigste Beteiligung darstellt, spielen Augenärzte eine wichtige Rolle bei der Versorgung der Betroffenen. Die Therapie ist oft langwierig und besteht primär in einer systemischen Immunsuppression.
Identifiants
pubmed: 37318615
doi: 10.1007/s00347-023-01880-y
pii: 10.1007/s00347-023-01880-y
doi:
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
779-790Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Chan LS, Razzaque Ahmed A, Anhalt GJ et al (2002) The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 138:370–379
doi: 10.1001/archderm.138.3.370
pubmed: 11902988
Ahmed AR, Hombal SM (1986) Cicatricial pemphigoid. Int J Dermatol 25:90–96. https://doi.org/10.1111/j.1365-4362.1986.tb04544.x
doi: 10.1111/j.1365-4362.1986.tb04544.x
pubmed: 3516897
Elder MJ, Bernauer W, Leonard J et al (1996) Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol 80:292–296
doi: 10.1136/bjo.80.4.292
pubmed: 8703876
pmcid: 505451
Holtsche MM, Zillikens D, Schmidt E (2018) Mucous membrane pemphigoid. Hautarzt 69:67–83. https://doi.org/10.1007/s00105-017-4089-y
doi: 10.1007/s00105-017-4089-y
pubmed: 29242962
Schmidt E, Meyer-Ter-Vehn T, Zillikens D et al (2008) Schleimhautpemphigoid mit okulärer Beteiligung Teil I: Klinik, Pathogenese und Diagnostik. Ophthalmologe 105:285–297. https://doi.org/10.1007/s00347-008-1699-x (quiz 298)
doi: 10.1007/s00347-008-1699-x
pubmed: 18335223
Hübner F, Recke A, Zillikens D et al (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol 136:2495–2498. https://doi.org/10.1016/j.jid.2016.07.013
doi: 10.1016/j.jid.2016.07.013
pubmed: 27456755
Bertram F, Bröcker EB, Zillikens D et al (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7:434–439. https://doi.org/10.1111/J.1610-0387.2008.06976.X
doi: 10.1111/J.1610-0387.2008.06976.X
pubmed: 19170813
Lee J, Seiffert-Sinha K, Attwood K et al (2019) A retrospective study of patient-reported data of bullous pemphigoid and mucous membrane pemphigoid from a US-based registry. Front Immunol. https://doi.org/10.3389/fimmu.2019.02219
doi: 10.3389/fimmu.2019.02219
pubmed: 32047498
pmcid: 6930882
Beek N, Weidinger A, Schneider SW et al (2021) Incidence of pemphigoid diseases in northern Germany in 2016—first data from the Schleswig-Holstein registry of autoimmune bullous diseases. J Eur Acad Dermatol Venereol 35:1197–1202. https://doi.org/10.1111/jdv.17107
doi: 10.1111/jdv.17107
pubmed: 33428263
Kharfi M, Khaled A, Anane R et al (2010) Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 27:119–124. https://doi.org/10.1111/j.1525-1470.2009.01079.x
doi: 10.1111/j.1525-1470.2009.01079.x
pubmed: 20537062
Thorne JE, Anhalt GJ, Jabs DA (2004) Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 111:45–52. https://doi.org/10.1016/j.ophtha.2003.03.001
doi: 10.1016/j.ophtha.2003.03.001
pubmed: 14711713
Radford CF, Rauz S, Williams GP et al (2012) Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in the United Kingdom. Eye (Lond) 26:1199–1208. https://doi.org/10.1038/eye.2012.119
doi: 10.1038/eye.2012.119
pubmed: 22722485
Dart JK (2017) The 2016 Bowman lecture conjunctival curses: scarring conjunctivitis 30 years on. Eye (Lond) 31:301–332. https://doi.org/10.1038/eye.2016.284
doi: 10.1038/eye.2016.284
pubmed: 28106896
Rübsam A, Klein J, Pleyer U (2013) Das okuläre vernarbende Pemphigoid – aktuelle Aspekte zu Klinik und Therapie einer problematischen Erkrankung. Klin Monbl Augenheilkd 230:796–803. https://doi.org/10.1055/s-0032-1328748
doi: 10.1055/s-0032-1328748
pubmed: 23959511
Mondino BJ, Brown SI (1981) Ocular cicatricial pemphigoid. Ophthalmology 88:95–100. https://doi.org/10.1016/S0161-6420(81)35069-6
doi: 10.1016/S0161-6420(81)35069-6
pubmed: 7015218
Foster CS (1986) Cicatricial pemphigoid. Trans Am Ophthalmol Soc 84:527–663
pubmed: 3296406
pmcid: 1298749
Ong HS, Minassian D, Rauz S et al (2020) Validation of a clinical assessment tool for cicatrising conjunctivitis. Ocul Surf 18:121–129. https://doi.org/10.1016/j.jtos.2019.10.010
doi: 10.1016/j.jtos.2019.10.010
pubmed: 31693934
Labowsky MT, Stinnett SS, Liss J et al (2017) Clinical implications of direct immunofluorescence findings in patients with ocular mucous membrane pemphigoid. Am J Ophthalmol 183:48–55. https://doi.org/10.1016/j.ajo.2017.08.009
doi: 10.1016/j.ajo.2017.08.009
pubmed: 28860044
De Rojas MV, Dart JKG, Saw VPJ (2007) The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 91:1048–1053. https://doi.org/10.1136/bjo.2006.109124
doi: 10.1136/bjo.2006.109124
pubmed: 17314145
pmcid: 1954786
Schmidt E, Nast A (2022) AWMF-S2k-Leitlinie Diagnostik und Therapie des Schleimhautpemphigoids (AWMF-Register-Nr: 013-102, 2022)
Rashid H, Lamberts A, Borradori L et al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology—part I. J Eur Acad Dermatol Venereol 35:1750–1764. https://doi.org/10.1111/JDV.17397
doi: 10.1111/JDV.17397
pubmed: 34245180
pmcid: 8457055
Schmidt E, Rashid H, Marzano AV et al (2021) European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology—part II. Acad Dermatol Venereol. https://doi.org/10.1111/JDV.17395
doi: 10.1111/JDV.17395
Oyama N, Setterfield JF, Powell AM et al (2006) Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 154:90–98. https://doi.org/10.1111/j.1365-2133.2005.06998.x
doi: 10.1111/j.1365-2133.2005.06998.x
pubmed: 16403100
Murakami H, Nishioka S, Setterfield J et al (1998) Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. J Dermatol Sci 17:39–44. https://doi.org/10.1016/S0923-1811(97)00067-4
doi: 10.1016/S0923-1811(97)00067-4
pubmed: 9651827
Schmidt E, Skrobek C, Kromminga A et al (2001) Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 145:778–783. https://doi.org/10.1046/j.1365-2133.2001.04471.x
doi: 10.1046/j.1365-2133.2001.04471.x
pubmed: 11736901
Bernard P, Antonicelli F, Bedane C et al (2013) Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 149:533–540. https://doi.org/10.1001/jamadermatol.2013.1434
doi: 10.1001/jamadermatol.2013.1434
pubmed: 23426192
Therapieinformationsbögen. https://dgrh.de/Start/Versorgung/Therapieinformationen/Therapieinformationsb%C3%B6gen.html ;. Zugegriffen: 8. Juni 2021
Saw VPJ, Dart JKG, Rauz S et al (2007) Immunosuppressive therapy for ocular mucous membrane pemphigoid. Ophthalmology 115:253–261.e1. https://doi.org/10.1016/j.ophtha.2007.04.027
doi: 10.1016/j.ophtha.2007.04.027
pubmed: 17655931
Foster CS (1980) Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 87:140–150. https://doi.org/10.1016/S0161-6420(80)35272-X
doi: 10.1016/S0161-6420(80)35272-X
pubmed: 6992019
Gangaputra S, Newcomb CW, Liesegang TL et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116:2188–2198.e1. https://doi.org/10.1016/j.ophtha.2009.04.020
doi: 10.1016/j.ophtha.2009.04.020
pubmed: 19748676
Elder MJ, Lightman S, Dart JK (1995) Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 79:264–266. https://doi.org/10.1136/bjo.79.3.264
doi: 10.1136/bjo.79.3.264
pubmed: 7703207
pmcid: 505076
Pujari SS, Kempen JH, Newcomb CW et al (2010) Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 117:356–365. https://doi.org/10.1016/j.ophtha.2009.06.060
doi: 10.1016/j.ophtha.2009.06.060
pubmed: 19969366
Letko E, Miserocchi E, Daoud YJ et al (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303–310. https://doi.org/10.1016/j.clim.2003.11.002
doi: 10.1016/j.clim.2003.11.002
pubmed: 15183151
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M et al (2011) Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 147:843–849. https://doi.org/10.1001/archdermatol.2011.54
doi: 10.1001/archdermatol.2011.54
pubmed: 21422323
Rübsam A, Stefaniak R, Worm M et al (2015) Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 15:927–933
doi: 10.1517/14712598.2015.1046833
pubmed: 25966960
Maley A, Warren M, Haberman I et al (2016) Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 74:835–840. https://doi.org/10.1016/j.jaad.2016.01.020
doi: 10.1016/j.jaad.2016.01.020
pubmed: 26936298
Elder MJ, Dart JK, Collin R (1995) Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol 79:1003–1006. https://doi.org/10.1136/bjo.79.11.1003
doi: 10.1136/bjo.79.11.1003
pubmed: 8534641
pmcid: 505315
Neff AG (2008) Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag 4:617–626. https://doi.org/10.2147/TCRM.S1140
doi: 10.2147/TCRM.S1140
pubmed: 18827857
pmcid: 2500254
Geerling G, Dart JKG (2000) Management and outcome of cataract surgery in ocular cicatricial pemphigoid. Graefes Arch Clin Exp Ophthalmol 238:112–118. https://doi.org/10.1007/PL00007877
doi: 10.1007/PL00007877
pubmed: 10766278
Schmidt E, Benoit S, Kampik D et al (2017) Tibial bone keratoprosthesis: reversing blindness in mucous membrane pemphigoid. J Dtsch Dermatol Ges 15:1024–1026
pubmed: 28976093
Geerling G, Hille K (2017) Zum Stand der Keratoprothesen mit biologischer Haptik – Die Düsseldorf-Offenburger-Erfahrungen mit Osteo-Odonto- und Tibia-Keratoprothese. Klin Monbl Augenheilkd 234:763–769. https://doi.org/10.1055/s-0043-111086
doi: 10.1055/s-0043-111086
pubmed: 28586929